{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:40:02Z","timestamp":1751276402505,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s41669-025-00576-0","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:19:47Z","timestamp":1744737587000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Validation of Estimation of Health Utility Values in Alopecia Areata"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-2130","authenticated-orcid":false,"given":"Caleb","family":"Dixon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7091-1274","authenticated-orcid":false,"given":"Elin","family":"Gruffydd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"1","key":"576_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011. https:\/\/doi.org\/10.1038\/nrdp.2017.11.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"576_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370. https:\/\/doi.org\/10.1111\/ajd.12941.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"576_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.032.","journal-title":"J Am Acad Dermatol"},{"key":"576_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/ccid.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/ccid.S53985.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"576_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich SH, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383. https:\/\/doi.org\/10.1007\/s13555-021-00512-0.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"576_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Wikonk\u00e1l N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561\u201371. https:\/\/doi.org\/10.1111\/bjd.14497.","journal-title":"Br J Dermatol"},{"issue":"2","key":"576_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13555-021-00508-w","volume":"11","author":"R Winnette","year":"2021","unstructured":"Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther (Heidelb). 2021;11(2):599\u2013613. https:\/\/doi.org\/10.1007\/s13555-021-00508-w.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"576_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bodyim.2009.03.004","volume":"6","author":"N Welsh","year":"2009","unstructured":"Welsh N, Guy A. The lived experience of alopecia areata: a qualitative study. Body Image. 2009;6(3):194\u2013200. https:\/\/doi.org\/10.1016\/j.bodyim.2009.03.004.","journal-title":"Body Image"},{"key":"576_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/983804","volume":"2013","author":"J Masmoudi","year":"2013","unstructured":"Masmoudi J, Sellami R, Ouali U, Mnif L, Feki I, Amouri M, et al. Quality of life in alopecia areata: a sample of Tunisian patients. Dermatol Res Pract. 2013;2013:983804. https:\/\/doi.org\/10.1155\/2013\/983804.","journal-title":"Dermatol Res Pract"},{"issue":"4","key":"576_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806\u201312.e3. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.035.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"576_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/ijt.ijt_93_18","volume":"10","author":"SJ Li","year":"2018","unstructured":"Li SJ, Huang KP, Joyce C, Mostaghimi A. The impact of alopecia areata on sexual quality of life. Int J Trichol. 2018;10(6):271\u20134. https:\/\/doi.org\/10.4103\/ijt.ijt_93_18.","journal-title":"Int J Trichol."},{"issue":"5","key":"576_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916\u201326. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10955.x.","journal-title":"Br J Dermatol"},{"issue":"18","key":"576_CR13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"576_CR14","unstructured":"European Medicines Agency. Olumiant (baricitinib): an overview of Olumiant and why it is authorised in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/olumiant-epar-medicine-overview_en.pdf. Accessed 27 Nov 2024."},{"key":"576_CR15","unstructured":"Pfizer. Litfulo (ritlecitinib) [prescribing information]. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed 27 Nov 2024."},{"key":"576_CR16","unstructured":"National Institute for Clinical Excellence. NICE health technology evaluations: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed 27 Nov 2024."},{"key":"576_CR17","unstructured":"National Institute for Clinical Excellence. Baricitinib for treating moderate to severe atopic dermatitis. 2021. https:\/\/www.nice.org.uk\/guidance\/ta681\/chapter\/1-Recommendations#:~:text=1.1%20Baricitinib%20is%20recommended%20as,these%20are%20not%20suitable%2C%20and. Accessed 27 Nov 2024."},{"issue":"12","key":"576_CR18","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1016\/j.jval.2022.09.2133","volume":"25","author":"A Bewley","year":"2022","unstructured":"Bewley A, Va\u00f1\u00f3 Galv\u00e1n S, Johansson E, Austin J, Durand F, Petto H, et al. PCR200 Measuring the burden of alopecia areata with the European Quality of Life-5 Dimensions (EQ-5D): results from a real-world survey in 5 European countries. Value Health. 2022;25(12):S428\u20139. https:\/\/doi.org\/10.1016\/j.jval.2022.09.2133.","journal-title":"Value Health."},{"issue":"3","key":"576_CR19","doi-asserted-by":"publisher","first-page":"AB86","DOI":"10.1016\/j.jaad.2021.06.368","volume":"85","author":"RT Burge","year":"2021","unstructured":"Burge RT, Anderson P, Austin J, Piercy J, Manuel L, Edson-Heredia E, et al. 26158 The patient-reported burden of alopecia areata by current severity: a real-world study in the US. J Am Acad Dermatol. 2021;85(3):AB86. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.368.","journal-title":"J Am Acad Dermatol"},{"key":"576_CR20","doi-asserted-by":"crossref","unstructured":"Lloyd AJ AD, Law EH, Price T. Does the EQ-5D measure the full impact of alopecia areata on patients\u2019 health related quality of life? Value Health (ISPOR 2023; Poster CO149). 2023.","DOI":"10.1016\/j.jval.2023.09.221"},{"key":"576_CR21","unstructured":"Rowen D, Brazier J, Wong R, Wailoo A. Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available. NICE DSU Report. 2020. https:\/\/www.sheffield.ac.uk\/media\/34046\/download?attachment. Accessed 27 Nov 2024."},{"issue":"6","key":"576_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.12.017.","journal-title":"Value Health."},{"issue":"6","key":"576_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s11136-024-03645-9","volume":"33","author":"D Aggio","year":"2024","unstructured":"Aggio D, Dixon C, Law EH, Randall R, Price T, Lloyd A. Estimation of health utility values for alopecia areata. Qual Life Res. 2024;33(6):1581\u201392. https:\/\/doi.org\/10.1007\/s11136-024-03645-9.","journal-title":"Qual Life Res"},{"key":"576_CR24","unstructured":"The Dental and Pharmaceutical Benefits Agency (Tandv\u00e5rds och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets, TLV). General guidelines for economic evaluations from the pharmaceutical benefits board. 2003. https:\/\/www.tlv.se\/download\/18.2e53241415e842ce95514e9\/1510316396792\/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf. Accessed 24 Nov 2024."},{"issue":"525","key":"576_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1468-0297.2007.02110.x","volume":"118","author":"P Dolan","year":"2007","unstructured":"Dolan P, Kahneman D. Interpretations of utility and their implications for the valuation of health. Econ J. 2007;118(525):215\u201334. https:\/\/doi.org\/10.1111\/j.1468-0297.2007.02110.x.","journal-title":"Econ J"},{"key":"576_CR26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"2","key":"576_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207. https:\/\/doi.org\/10.1007\/s40273-022-01218-7.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"576_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"KW Wyrwich","year":"2022","unstructured":"Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb). 2022;12(1):149\u201366. https:\/\/doi.org\/10.1007\/s13555-021-00648-z.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"576_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, Chiu WS, Gallardo WR, Nijher M, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365. https:\/\/doi.org\/10.1111\/bjd.20628.","journal-title":"Br J Dermatol"},{"issue":"9","key":"576_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jval.2021.02.012","volume":"24","author":"K Ludwig","year":"2021","unstructured":"Ludwig K, Ramos-Go\u00f1i JM, Oppe M, Kreimeier S, Greiner W. To what extent do patient preferences differ from general population preferences? Value Health. 2021;24(9):1343\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.02.012.","journal-title":"Value Health."},{"issue":"11","key":"576_CR31","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/jdv.15765","volume":"33","author":"K Hajdu","year":"2019","unstructured":"Hajdu K, Brodszky V, Stalmeier PFM, Ruzsa G, Tam\u00e1si B, Gul\u00e1csi L, et al. Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. J Eur Acad Dermatol Venereol. 2019;33(11):2106\u201313. https:\/\/doi.org\/10.1111\/jdv.15765.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"576_CR32","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"A Szende","year":"2013","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2013."},{"issue":"10","key":"576_CR33","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s11136-022-03141-y","volume":"31","author":"F Rencz","year":"2022","unstructured":"Rencz F, Mukuria C, Bat\u00f3 A, Po\u00f3r AK, Finch AP. A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Qual Life Res. 2022;31(10):3049\u201360. https:\/\/doi.org\/10.1007\/s11136-022-03141-y.","journal-title":"Qual Life Res"},{"issue":"6","key":"576_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1346-8138.16360","volume":"49","author":"E Edson-Heredia","year":"2022","unstructured":"Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan. J Dermatol. 2022;49(6):575\u201383. https:\/\/doi.org\/10.1111\/1346-8138.16360.","journal-title":"J Dermatol"},{"key":"576_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-024-01728-5","author":"\u00c1 Szab\u00f3","year":"2024","unstructured":"Szab\u00f3 \u00c1, Brodszky V, Rencz F. Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases. Eur J Health Econ. 2024. https:\/\/doi.org\/10.1007\/s10198-024-01728-5.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"576_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11136-023-03519-6","volume":"33","author":"E Szl\u00e1vicz","year":"2024","unstructured":"Szl\u00e1vicz E, Szab\u00f3 \u00c1, Kiny\u00f3 \u00c1, Szeiffert A, Bancs\u00f3k T, Brodszky V, et al. Content validity of the EQ-5D-5L with skin irritation and self-confidence bolt-ons in patients with atopic dermatitis: a qualitative think-aloud study. Qual Life Res. 2024;33(1):101\u201311. https:\/\/doi.org\/10.1007\/s11136-023-03519-6.","journal-title":"Qual Life Res"},{"key":"576_CR37","volume-title":"NICE decision support unit technical support documents. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values","author":"J Brazier","year":"2011","unstructured":"Brazier J, Rowen D. NICE decision support unit technical support documents. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: National Institute for Health and Care Excellence (NICE); 2011."},{"issue":"4","key":"576_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/jdv.17909","volume":"36","author":"R Winnette","year":"2022","unstructured":"Winnette R, Banerjee A, Sikirica V, Peeva E, Wyrwich K. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J Eur Acad Dermatol Venereol. 2022;36(4):602\u20139. https:\/\/doi.org\/10.1111\/jdv.17909.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"576_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2022.115227","volume":"309","author":"D Rowen","year":"2022","unstructured":"Rowen D, Mukuria C, Bray N, Carlton J, Longworth L, Meads D, et al. Assessing the comparative feasibility, acceptability and equivalence of videoconference interviews and face-to-face interviews using the time trade-off technique. Soc Sci Med. 2022;309:115227. https:\/\/doi.org\/10.1016\/j.socscimed.2022.115227.","journal-title":"Soc Sci Med"},{"key":"576_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114519","volume":"292","author":"AP Finch","year":"2022","unstructured":"Finch AP, Meregaglia M, Ciani O, Roudijk B, Jommi C. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med. 2022;292:114519. https:\/\/doi.org\/10.1016\/j.socscimed.2021.114519.","journal-title":"Soc Sci Med"},{"issue":"4","key":"576_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11136-010-9609-5","volume":"19","author":"R Norman","year":"2010","unstructured":"Norman R, King MT, Clarke D, Viney R, Cronin P, Street D. Does mode of administration matter? Comparison of online and face-to-face administration of a time trade-off task. Qual Life Res. 2010;19(4):499\u2013508. https:\/\/doi.org\/10.1007\/s11136-010-9609-5.","journal-title":"Qual Life Res"},{"issue":"5","key":"576_CR42","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s11136-020-02712-1","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Shaw J, M\u00fchlbacher A, Lee TA, Walton S, Kohlmann T, et al. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. Qual Life Res. 2021;30(5):1433\u201344. https:\/\/doi.org\/10.1007\/s11136-020-02712-1.","journal-title":"Qual Life Res"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00576-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:26:35Z","timestamp":1751275595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00576-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00576-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"24 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.L., T.P., A.L., C.D., and E.G. conceived the study and methodology. A.L., E.L., and T.P. validated the data, conducted project administration, and supervised the study. C.D. and E.G. performed the analysis and investigation and visualized the data. All authors wrote the first draft and reviewed and edited previous versions of the manuscript. All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was supported by Pfizer Inc, New York, USA, and the publication fees were covered by Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.D., E.G., and A.L. are employees of Acaster Lloyd Consulting Ltd, which was paid a fixed fee for working on this research project. A.L. is a stockholder in Acaster Lloyd Consulting Ltd. T.P. and E.H.L. are employees of and hold stock or stock options in Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The final protocol, any amendments, and informed consent documentation were reviewed and approved by an institutional review board and\/or independent ethics committee for each site participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Signed informed consent was obtained prior to participants entering the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The data were anonymized, and the submission does not include personal details or images that may lead to the identification of participants, and, therefore, consent to publish was not required.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}